S100A4 in cancer progression and metastasis: A systematic review

Fei Fei; Jie Qu; Mingqing Zhang; Yuwei Li; Shiwu Zhang

doi:10.18632/oncotarget.18016

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

S100A4 in cancer progression and metastasis: A systematic review

Fei Fei, Jie Qu, Mingqing Zhang, Yuwei Li and Shiwu Zhang _

PDF | HTML | How to cite

Oncotarget. 2017; 8:73219-73239. https://doi.org/10.18632/oncotarget.18016

Metrics: PDF 5136 views | HTML 7781 views | ?

Abstract

Fei Fei1,2, Jie Qu1,2, Mingqing Zhang3, Yuwei Li3 and Shiwu Zhang2

1Nankai University School of Medicine, Nankai University, Tianjin, 300071, P.R.China

2Department of Pathology, Tianjin Union Medical Center, Tianjin, 300121, P.R. China

3Department of Colorectal Surgery, Tianjin Union Medical Center, Tianjin, 300121, P.R. China

Correspondence to:

Shiwu Zhang, email: [email protected]

Keywords: S100A4, metastasis, malignant tumor, epithelial-mesenchymal transition

Received: April 11, 2017 Accepted: May 08, 2017 Published: May 19, 2017

ABSTRACT

Metastasis is the leading cause of cancer-related death and directly associates with cancer progression, resistance to anticancer therapy, and poor patient survival. Current efforts focusing on the underlying molecular mechanisms of cancer metastasis attract a special attention to cancer researchers. The epithelial-mesenchymal transition is a complex of molecular program during embryogenesis, inflammation, tissue fibrosis, and cancer progression and metastasis. S100A4, an important member of S100 family proteins, functions to increase the tumor progression and metastasis. The molecular mechanisms of S100A4 involving in the progression and metastasis are diverse in various malignant tumors. Detection of S100A4 expression becomes a promising candidate biomarker in cancer early diagnosis and prediction of cancer metastasis and therefore, S100A4 may be a therapeutic target. This review summarized up to date advancement on the role of S100A4 in human cancer development, progression, and metastasis and the underlying molecular events and then strategies to target S100A4 expression experimentally.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18016

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

S100A4 in cancer progression and metastasis: A systematic review

Abstract